Peter Llewellyn-davies
Member of the Supervisory Board
General Science
bti bioteach
Spain
Biography
Peter Llewellyn-Davies is a strategic CFO/CBO with an over 25 year track record in financing activities, international M&A deals, company turnarounds, licensing transactions and with particular experience in chemical and healthcare industries. Currently Peter supports small and medium sized companies with his consulting company Accellerate Partners, targeting in particular enterprises who require the support of a strategically orientated CFO but do not need a full time executive to cover this role. Peter is a non-executive Director and chair of the Audit Committee of Shield Therapeutics plc, who in 2016 completed an AIM listing in London. Peter was CFO/CBO of Medigene AG between 2012 and 2016 and supported the turnaround process by creating an equity story, outlicensing marketed and legacy products and enhancing shareholder value with a new large international investor base. Prior to that he was CFO of Wilex AG, having orchestrated their IPO in 2006 to fund a later stage pipeline, setting up investor and public relations and concluding subsequent partnering deals and acquisitions. Prior to this, he was Executive Director of Müller Dairy (UK) Ltd and Executive Director Finance at Süd-Chemie AG. Peter read business management, banking, marketing and controlling in London, St. Gallen and Munich, and has a certiï¬cate in business studies from the University of London.
Research Interest
General Science
